Literature DB >> 17296813

Management of gastroesophageal tumors.

Denise W Gee1, David W Rattner.   

Abstract

The incidence of adenocarcinomas of the gastroesophageal junction has increased in recent years. These tumors possess distinct pathophysiologic characteristics. Although the consensus is that an R0 resection (complete microscopic and macroscopic resection) is the goal when operating for curative intent, much controversy remains regarding other aspects of patient management. There is lack of consensus regarding the type of surgery to perform, the role and extent of lymphadenectomy, and the role of neoadjuvant therapy. Utilizing an evidence-based approach, this review article provides an overview of the management of gastroesophageal junction carcinomas with particular emphasis on current areas of controversy.

Entities:  

Mesh:

Year:  2007        PMID: 17296813     DOI: 10.1634/theoncologist.12-2-175

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  13 in total

Review 1.  Neoadjuvant treatment of esophageal cancer.

Authors:  Nicholas P Campbell; Victoria M Villaflor
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

2.  Detection of lymph node involvement by cytokeratin immunohistochemistry is an independent prognostic factor after curative resection of esophageal cancer.

Authors:  Goran Marjanovic; Markus Schricker; Axel Walch; Axel zur Hausen; Ulrich T Hopt; Andreas Imdahl; Frank Makowiec
Journal:  J Gastrointest Surg       Date:  2010-10-26       Impact factor: 3.452

3.  Effect of lymphadenectomy extent on advanced gastric cancer located in the cardia and fundus.

Authors:  Chang-Ming Huang; Bi-Juan Lin; Hui-Shan Lu; Xiang-Fu Zhang; Ping Li; Jian-Wei Xie
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

4.  Prognostic impact of metastatic lymph node ratio in advanced gastric cancer from cardia and fundus.

Authors:  Chang-Ming Huang; Bi-Juan Lin; Hui-Shan Lu; Xiang-Fu Zhang; Ping Li; Jian-Wei Xie
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

5.  Refining docetaxel-containing therapy for gastric cancer.

Authors:  Nushmia Z Khokhar; Yixing Jiang; Al B Benson; Jaffer A Ajani; Mary F Mulcahy
Journal:  Gastrointest Cancer Res       Date:  2011-05

Review 6.  Multimodality management of resectable gastric cancer: A review.

Authors:  Helen Shum; Lakshmi Rajdev
Journal:  World J Gastrointest Oncol       Date:  2014-10-15

7.  Prognosis of patients with gastric cancer and solitary lymph node metastasis.

Authors:  Chun-Qiu Chen; Xiao-Jiang Wu; Zhen Yu; Zhao-De Bu; Ke-Qiang Zuo; Zi-Yu Li; Jia-Fu Ji
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

8.  National Trends in Utilization of Endoscopic Ultrasound for Gastric Cancer: a SEER-Medicare Study.

Authors:  Ciara R Huntington; Kendall Walsh; Yimei Han; Jonathan Salo; Joshua Hill
Journal:  J Gastrointest Surg       Date:  2015-11-09       Impact factor: 3.452

9.  Nano-curcumin inhibits proliferation of esophageal adenocarcinoma cells and enhances the T cell mediated immune response.

Authors:  Francesca Milano; Luigi Mari; Wendy van de Luijtgaarden; Kaushal Parikh; Silvia Calpe; Kausilia K Krishnadath
Journal:  Front Oncol       Date:  2013-05-29       Impact factor: 6.244

10.  Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer.

Authors:  Qi-Wei Wang; Xiao-Tian Zhang; Ming Lu; Lin Shen
Journal:  World J Gastrointest Oncol       Date:  2018-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.